OCEAN(a)-Outcomes (TIMI 75)

The primary objective of this study is to evaluate the efficacy and safety of lowering lipoprotein(a) through RNA interference with olpasiran in participants with atherosclerotic cardiovascular disease and elevated lipoprotein(a) concentrations.

Ocean(a) Outcomes Study Design 10-17-2022 (002)

OCEAN(a)-Outcomes (TIMI 75) on ClinicalTrials.gov

CONTACT US about OCEAN(a)-Outcomes

%d bloggers like this:
search previous next tag category expand menu location phone mail time cart zoom edit close